Cardiometabolic Effects of a New Class of Antidiabetic Agents

Clinical Therapeutics
Cyrus V DesouzaAnery Patel

Abstract

Within the past decade, many new classes of drugs have received approval from the US Food and Drug Administration for treatment of type 2 diabetes mellitus, including glucagon-like peptide-1agonists, dipeptidyl peptidase-4 inhibitors, and the sodium-glucose cotransporter-2 inhibitors. Many trials have been performed, and several more are currently ongoing to evaluate these drugs. This review addresses the broad therapeutic and pleiotropic effects of these drugs. The review also discusses the role of these drugs in the treatment paradigm for type 2 diabetes and identifies patients who would be suitable candidates for treatment with these drugs. In this comprehensive evidence-based review, the following databases were searched from 1990 to the present: PubMed/MEDLINE, Scopus, CINAHL, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Portal, and the American Diabetes Association and European Association for the Study of Diabetes abstract databases. Randomized clinical trials (RCTs) were only included for the main therapeutic and cardiovascular (CV) effects of these drug classes. For pleiotropic effects, RCTs were included unless no RCTs exist, in which case other studies as specified in the d...Continue Reading

References

Jun 22, 2007·Vascular Health and Risk Management·Baptist Gallwitz
Jul 12, 2007·JAMA : the Journal of the American Medical Association·Renee E AmoriAnastassios G Pittas
Oct 12, 2007·Physiological Reviews·Jens Juul Holst
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Oct 6, 2009·Journal of the American Pharmacists Association : JAPhA·John White
Mar 11, 2010·Diabetes Care·John B BuseUNKNOWN DURATION-1 Study Group
Jan 14, 2011·Diabetes, Obesity & Metabolism·A J TremblayP Couture
Feb 11, 2011·British Journal of Clinical Pharmacology·Arne RingKlaus A Dugi
Feb 11, 2011·Diabetes/metabolism Research and Reviews·Matteo MonamiEdoardo Mannucci
Jul 9, 2011·Cardiovascular Diabetology·Sameer AnsarPeter D Reaven
Oct 28, 2011·The Journal of Clinical Endocrinology and Metabolism·Belinda GierMichael W Yeh
Nov 10, 2011·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Shridhar N IyerRobert J Tanenberg
Apr 13, 2012·Circulation. Cardiovascular Interventions·Jacob LønborgThomas Engstrøm
Jun 19, 2012·The American Journal of Cardiology·Harshal R PatilJames H O'Keefe
Jun 27, 2012·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Concetta IraceAgostino Gnasso
Nov 9, 2012·The Annals of Pharmacotherapy·Haesuk ParkKaren L Rascati

❮ Previous
Next ❯

Citations

Jan 24, 2016·Biochemical and Biophysical Research Communications·Yuki TanakaHiroshi Maegawa
Jun 9, 2016·Expert Opinion on Drug Safety·Lisa M YounkStephen N Davis
Jun 17, 2016·Current Medical Research and Opinion·Niki KatsikiDimitri P Mikhailidis
Sep 26, 2019·Heart·Gaurav S GulsinGerry P McCann
Aug 9, 2019·World Journal of Gastroenterology : WJG·Anastasia Kontana, Konstantinos Tziomalos
Sep 2, 2017·Geriatrics & Gerontology International·Takahiro KambaraMasayoshi Ajioka
Nov 22, 2019·Current Diabetes Reports·Laleh Razavi-Nematollahi, Faramarz Ismail-Beigi
Sep 5, 2017·Frontiers in Physiology·Sandra Feijóo-BandínFrancisca Lago
Mar 12, 2021·British Journal of Clinical Pharmacology·Rumiko Shimazawa, Masayuki Ikeda
Jul 24, 2021·The Journal of Membrane Biology·Jiang LiuJoseph I Shapiro
Aug 2, 2021·Romanian Journal of Internal Medicine = Revue Roumaine De Médecine Interne·Justin T CallDana M Harris
Aug 28, 2021·Cells·Walter MassonJuan Patricio Nogueira
Aug 2, 2017·Clinical Diabetes : a Publication of the American Diabetes Association·Richard E Pratley, Eugenio Cersosimo

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Cardiovascular Risk Reduction

Prevention of cardiovascular disease is an important health initiative. Risk reduction including physical activity, smoking cessation, diet, blood pressure lowering drugs and pharmacotherapy. Here is the latest research on cardiovascular risk reduction.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.